Arrowhead Pharmaceuticals (ARWR) FY2016 results: revenue $158,333, down 58.6% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $158,333 for fiscal 2016, the year ended 30 September 2016, down 58.6% on the year before. Net income was -$82 million, and diluted earnings per share $-1.34. The figures are the company's own, from the 10-K it filed with the SEC on 14 December 2016.
Revenue
$158,333
-58.6% on the year
FY2011FY2016
Operating margin
-51627.1%
-25124.1% a year earlier
FY2011FY2016
Net income
-$82 million
FY2011FY2016
Diluted EPS
-$1.34
FY2011FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
0.2
0.4
0.2
-58.6%
Research and development
62.1
47.3
23.1
+31.4%
Operating income
-81.7
-96.0
-53.3
Operating margin
-51627.1%
-25124.1%
-30443.6%
Pre-tax income
-81.7
-91.9
-58.7
Income tax
0.0
0.0
0.0
0.0%
Net income
-81.7
-91.9
-58.6
Net margin
-51614.6%
-24068.3%
-33503.0%
Diluted EPS
-$1.34
-$1.60
-$1.25
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-64.4
-65.7
-35.4
Capital expenditure
3.9
2.0
1.7
+95.9%
Free cash flow
-68.3
-67.7
-37.1
Free cash flow margin
-43129.2%
-17716.8%
-21219.3%
Cash from investing
13.4
n/a
n/a
Cash from financing
55.1
n/a
n/a
Depreciation and amortisation
3.3
2.3
1.3
+39.5%
Share-based compensation
11.6
10.2
5.7
+13.3%
Shares outstanding at period end
70m
60m
55m
+17.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
95.6
110
167
-13.2%
Non-controlling interest
-0.6
-0.6
-0.6
Debt
2.5
0.0
0.1
Other liabilities
30.6
22.6
16.8
+35.2%
Total liabilities and equity
128
132
183
-3.1%
Fixed assets
15.4
4.5
3.9
+239.9%
Intangible assets
22.2
24.8
1.0
-10.7%
Investments
n/a
n/a
44.7
Securities held for sale or to maturity
n/a
17.5
n/a
Cash and equivalents
85.4
81.2
133
+5.1%
Receivables
0.1
n/a
n/a
Other assets
5.2
4.2
0.7
+24.5%
Total assets
128
132
183
-3.1%
10-K for the year ended 30 September 2016, filed 14 December 2016: the filing.